CD4 and non-small cell lung carcinoma: It can be transferred from tumor cells to platelets in a fibronectin 1-, integrin α5β1- and GPIbα-dependent manner in non-small cell lung cancer (NSCLC), and platelet PD-L1 possesses the ability to inhibit the function of CD4+ and CD8+ T cells (118).